Lexology August 9, 2023
McDermott Will & Emery

Key players across the healthcare industry—including sponsors, contract research organizations (CROs), research sites, regulators and patient advocates—are well aware of the challenges associated with the prompt and effective identification and enrollment of study subjects. In this context, stakeholders should consider several important factors when developing and implementing study pre-screening and recruitment activities.

In Depth

Delays or failures in launching clinical trials can lead to millions of dollars in costs for sponsors and impede access to new or improved therapies and diagnostics for patients. As services and initiatives designed to address these challenges proliferate, it is important to consider key factors that can trigger legal, operational and business risks.

  1. Data Use and Sharing. It is important to consider what data...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Clinical Trials, FDA, Govt Agencies, HIPAA, Trends
Pregnant People Can Freely Make Decisions About Participation In Clinical Research
InnovationRx: Positive Clinical Trial Results For Generative AI-Designed Drug
Copayment Burden Affects Medication Adherence in Chronic Conditions
Neurogene hits a setback in the clinic, days after fundraise
How to adapt to choppy waters in biotech ecosystem

Share This Article